Skip to main content

Is the estimate of the cost of funding Pharmac's Options for Investment list provided in Pharmac's response to official information act request number 2025-26-228 inclusive of the cost of Wegovy and Monjaro?

Answered Question 32906 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Is the estimate of the cost of funding Pharmac's Options for Investment list provided in Pharmac's response to official information act request number 2025-26-228 inclusive of the cost of Wegovy and Monjaro?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

I am advised that the cost of funding Pharmac’s Options for Investment (OFI) list is inclusive of all items ranked as of May 2026, which includes semaglutide (Wegovy brand). However, the figure does not include the cost of tirzepatide (Mounjaro) as this funding application is still under assessment, and was not on the OFI at the time.